Compare OCFC & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | FLGT |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 867.4M |
| IPO Year | 1996 | 2016 |
| Metric | OCFC | FLGT |
|---|---|---|
| Price | $19.22 | $23.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $21.33 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 778.7K | 196.7K |
| Earning Date | 01-22-2026 | 02-27-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $388,753,000.00 | $315,549,000.00 |
| Revenue This Year | $46.71 | $16.84 |
| Revenue Next Year | $21.25 | $9.74 |
| P/E Ratio | $16.74 | ★ N/A |
| Revenue Growth | 3.60 | ★ 13.61 |
| 52 Week Low | $14.29 | $14.57 |
| 52 Week High | $20.61 | $31.04 |
| Indicator | OCFC | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 55.51 | 25.57 |
| Support Level | $18.15 | $22.76 |
| Resistance Level | $20.02 | $26.74 |
| Average True Range (ATR) | 0.58 | 0.82 |
| MACD | 0.12 | -0.46 |
| Stochastic Oscillator | 60.90 | 8.96 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.